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Summary The Barostim neo™ system is a novel implant-
able device that activates the carotid baroreflex. It 
decreases the sympathetic activity and inhibits the 
renin system, which results in reduced blood pressure 
and heart rate. In patients with resistant hypertension, 
electrically activation of the baroreflex leads to an aver-
age decrease in systolic blood pressure of 38, 36, 40 and 
53 mmHg at 1, 2, 3 and 4 years, respectively. Additionally, 
cardiac remodelling with reduced left ventricular mass 
and posterior wall thickness has been observed in long-
term studies. In a limited number of patients with heart 
failure, baroreflex activation therapy leads to a decrease 
in muscle sympathetic nerve activity and to improved 
quality of life and functional capacities. The implantation 
procedure is safe and associated with risks comparable 
with those of other active implantable devices. Barostim 
neo™ is currently available in several European countries.
Keywords Baroreflex activation therapy · Drug-resistant 
hypertension · Heart failure · Barostim neo™
Interventionelle kardiovaskuläre Therapie bei 
Bluthochdruck
Zusammenfassung Das Barostim neo™ System ist ein 
neues Gerät, welches elektrisch den Baroreflex-Me-
chanismus aktiviert (Karotisstimulator). Durch die 
Reduktion des Sympathikotonus und das Dämpfen das 
Renin-Systems bewirkt es ein Absenken von Blutdruck 
und Herzfrequenz. Bei Patienten mit therapierefraktä-
rer Hypertonie führte die elektrische Aktivierung des 
Baroreflexes im Langzeit-Verlauf zu einer dauerhaften 
durchschnittlichen Senkung des systolischen Blutdrucks 
um 38, 36, 40 und 53 mmHg nach 1, 2, 3 und 4 Jahren. Aus-
serdem konnte bei diesen Patienten eine Reduktion der 
links-ventrikulären Masse und der posterioren Wanddi-
cke beobachtet werden. Bei einigen Patienten mit Herz-
insuffizienz konnte eine Reduktion der sympathischen 
Muskelaktivität bewirkt werden und eine wesentliche 
Verbesserung der Lebensqualität und der körperlichen 
Leistung beobachtet werden. Die Implantation des Gerä-
tes gilt als sicher; die Risiken sind vergleichbar mit ande-
ren implantierbaren Stimulatoren. Barostim neo™ ist nun 
in mehreren europäischen Ländern erhältlich.
Schlüsselwörter Elektrische Baroreflex Aktivierung  · 
Therapierefraktäre Hypertonie  · Herzinsuffizienz  · Bar-
ostim neo™
Introduction
Arterial hypertension, defined as systolic blood pressure 
(SBP) above 140 mmHg or diastolic blood pressure above 
90 mmHg, affects more than 30 % of adults in the western 
world. Patients with a blood pressure of 140/90  mmHg 
have a risk for cardiac events twice as high as those with 
blood pressures of less than 130/80 mmHg, and the risk 
of cardiovascular death doubles with each increment of 
20/10 mmHg above 115/75 mmHg [1]. Similarly, effective 
antihypertensive treatment is able to reduce the risk for 
stroke, myocardial infarction and congestive heart failure 
by up to 50 % [2, 3]. However, hypertension can be effec-
tively treated by best medical treatment (i.e. lowered to 
pressures of 140/90 mmHg or below) only in 25–34 % of 
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patients, as many patients are resistant to medical treat-
ment or demonstrated limited adherence to lifelong 
therapy [1]. And many of these resistant patients suffer 
from hypertension severe enough to place them at immi-
nent risk of virulent cardiovascular disease.
So far, blood pressure management is dominated 
by antihypertensive medication. But, other non-drug-
related therapeutic options have been advocated in 
the past decade: electrical baroreceptor stimulation, 
biofeedback and other psychosomatic approaches, 
renal artery denervation as well as vaccination against 
high blood pressure. Unfortunately, the last two treat-
ment modalities (renal artery denervation and vacci-
nation) have recently been shown to be unsuccessful 
[4, 5]. In contrast, electrical stimulation of the carotid 
sinus baroreflex is known to decrease blood pressure 
via intrinsic neurohumoral pathways [6] and represents 
a valuable therapeutic adjunct in patients with resistant 
hypertension.
The aim of this paper is to review the pathophysiologi-
cal mechanisms of carotid baroreflex, to describe the 
second generation neurostimulating devices and associ-
ated surgical techniques and to summarise the current 
results in the treatment of resistant arterial hypertension.
History
The importance of the baroreflex for blood pressure regu-
lation has already been recognised many decades ago [7]. 
In humans, baroreceptors are situated mainly in the aor-
tic arch, the subclavian arteries and the carotid sinuses 
of which the dominant one is the carotid baroreflex. 
The anatomical distribution and feedback mechanisms 
of the baroreceptor nerve fibres have been investigated 
extensively [8] (Figs. 1 and 2). In brief, raising blood pres-
sure increases stretch of the carotid sinus wall and sub-
sequently activates the distortion receptors known as 
baroreceptors in the carotid sinus wall, which results in 
an increased frequency and amplitude of afferent nerve 
impulses. These impulses are then integrated in the 
medulla where neurohumoral and autonomic nervous 
system activities are modulated leading to an adjusted 
function of the heart, the kidneys and the peripheral vas-
culature resistance, which in turn leads to appropriate 
arterial pressure levels again.
Accordingly, electrical stimulation of the carotid sinus 
nerve reduces blood pressure and heart rate. As early as 
the 1960s and 1970s, carotid baroreflex stimulation was 
used to support the treatment of resistant hypertension 
in selected patients [6]. The approach, however, was 
aborted not only due to the limitations of the implant-
able devices and the development of more potent medi-
cation but also due to industry’s preferred interest in 
the pacemaker development at the time. Some treated 
patients, however, were investigated decades later [9]. 
These observations demonstrated together with more 
recent data from animal studies that carotid baroreflex 
stimulation is indeed able to influence the long-term 
regulation of arterial blood pressure [10, 11].
Device and surgical technique
The first-generation device was the Rheos System Barore-
flex Activation Therapy Device® (CVRx Inc., Minneapolis, 
MN, USA) consisting of bilateral carotid sinus leads and a 
battery powered, programmable internal pulse generator 
(IPG). Thereby, the leads conduct the activation energy 
from the pulse generator to the baroreceptor fibres in 
the vessel walls of both carotid sinuses. The device is 
telemetrically programmable by an external system, 
which allows non-invasive adjustments of the stimula-
tion parameters. The new generation device includes an 
IPG and only one lead. Therefore, baroreceptor stimu-
lation is now performed only unilaterally. Moreover, 
the electrode and the IPG have become much smaller 
(Figs. 3 and 4) and further refinements in hardware and 
software have lead to battery longevity of 48 months on 
average, depending on the unique programming for each 
patient. The new design employs monopolar stimulation 
with the IPG serving as an active electrode. The design 
allows for greater penetration of the electrical current 
Fig. 1 Carotid bifurcation in man. In the carotid sinus one may 
distinguish a proximal elastic portion (E.P.) abundantly sup-
plied with baroreceptors (+), an intermediate portion (I.P.) and 
a distal muscular portion (M.P.). The artery (a) of the carotid 
body (g) has elastic structure and arises from the root of the 
external carotid. Common carotid (C.C.), internal carotid (C.I.), 
external carotid (C.E.). [8]
 
main topic
510  Electrical carotid baroreceptor stimulation 1 3
to the neurovascular bundle and, thus, to the baroreflex 
[12]. So far, all procedures have been performed under 
general anaesthesia and any antihypertensive medica-
tion is maintained during the perioperative phase, except 
for beta-adrenergic blockers.
For the carotid sinus lead application and their intra-
operative testing, any inhalational anaesthetics should 
be reduced and (partly) replaced by barbiturates or ben-
zodiazepines to avoid pharmacological inhibition of 
the baroreflex [12]. Then, the electrode is positioned in 
various locations on the carotid bifurcation and electrical 
stimulation is started to localise the optimum haemody-
into the media of carotid artery where the baroreceptors 
are located, and the output of the IPG is now delivered a 
constant current.
During surgical device implantation, the patient is 
positioned in a supine position so that the two incisions 
can be accessed easily, one over the right carotid bifur-
cation and the other just beneath the right collarbone 
(Fig. 5). The carotid artery bifurcation is exposed and the 
anterior wall of the carotid sinus mobilised, while the 
vagal nerve as well as the superior root of the ansa cervi-
calis nervi hypoglossi are protected. Crucially, dissection 
within the bifurcation must be avoided to prevent injury 
Fig. 3 First (Rheos®) and 
second (Barostim neo™) gen-
eration baroreflex activation 
systems
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Patients with resistant hypertension
The Device Based Therapy in Hypertension (DEBuT-
HT) Trial was a prospective, non-randomised European 
multi-centre feasibility and safety study and involved 45 
patients with a SBP above 160 mmHg despite a treatment 
regimen comprising at least three antihypertensive drugs 
including one diuretic [14]. Patients remained on anti-
hypertensive medication during the study. The primary 
endpoint was a decrease of SBP of at least 10 mmHg after 
3 months of device therapy; safety assessment included 
any serious adverse events and all procedure- and device-
related events of any severity up to 3 years of follow-up. 
Mean systolic pressure before implantation was almost 
180 mmHg and mean heart rate was 80 beats/min. Partic-
ipants were taking 5.5 antihypertensive drugs on average. 
After 3 months, mean pressures were reduced by more 
than 20  mmHg. At 2- and 3-year follow-up, this result 
was not only sustained, but the mean reduction was even 
more pronounced at over 30 mmHg [14] (Fig. 6). Besides, 
the device exhibited an acceptable safety profile, and 
patients reported a better sleep and less headache and 
they could better concentrate since start of the therapy.
As a result of these findings, the US Food and Drug 
Administration approved a phase III trial (Rheos® Pivotal 
namic response (‘mapping’). Once the optimal location 
is confirmed, the electrode is sutured in place. A strain 
relief loop is formed and fixed to the common carotid 
artery. Afterwards, the lead is tunnelled subcutaneously 
first towards the jugulum and second in a 90-degree 
angle towards the incision for the pulse generator. Sub-
sequently, the pulse generator is implanted and con-
nected to the lead. Implantation can be performed as 
day-case surgery. Continuous baroreflex stimulation is 
programmed and initiated 2–4 weeks after implantation.
Clinical studies
In the acute BaroReceptor Activation System Study 
(BRASS), the temporary effects of carotid baroreflex 
stimulation was investigated during elective carotid sur-
gery [13]. With incremental voltage a significant dose-
dependent blood pressure and heart rate reduction were 
achieved. Maximum reductions occurred at 4–6 V. Thus, 
BRASS reconfirmed the assumption that device-based 
baroreflex stimulation was able to modulate blood pres-
sure acutely. This proof of concept justified the evalua-
tion of the system regarding chronic pressure reduction 
in hypertensive patients.
Fig. 5 Illustration of the 
Barostim neoTM system con-
sisting of a unilateral electrode 
and lead and an implantable 
pulse generator. Programming 
is performed via radiofrequen-
cy telemetry by an external 
laptop-based programmer
 
Fig. 4 Surface of electrode tip 
touching the carotid wall (uni-
polar design, 2-mm diameter 
coated cathode) and implant-
able pulse generator of the 
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patients with symptomatic heart failure, chronic Rheos® 
therapy improved functional capacity by as much as 37 % 
when measured by a 6-min hall walk test. Thereby, sig-
nificant reductions of left ventricular mass and posterior 
wall thickness indicated relevant reverse left ventricu-
lar remodelling. In addition, the Rheos® device was also 
effective in the management of uncontrollable hyperten-
sion [20].
Of note, all aforementioned studies were performed 
with the first-generation device using bilateral leads and 
electrodes. A recently published study showed that BAT 
delivered with the second-generation system (Barostim 
neo) lowers blood pressure in resistant hypertension with 
stable, intensive background medical therapy, consis-
tent with studies of the first-generation system (Rheos). 
Besides, the safety profile was described as comparable 
with a pacemaker [21].
A major concern of the BAT is the potential devel-
opment of decreasing responsiveness (tachyphylaxis 
or baroreflex resetting). But, a follow-up study of the 
DEBuT-HT patients demonstrated that acute voltage-
dependent blood pressure and heart rate decrease are 
preserved after at least 1 year of continuous electrical 
baroreflex stimulation in patients with resistant hyper-
tension [22]. This indicates that response adaptation and 
nerve fatigue are unlikely to develop in long-term carotid 
baroreflex activation.
The described studies led to the incorporation of BAT 
into treatment guidelines. According to the new 2013 
European Society of Hypertension (ESH)/European 
Society of Cardiology (ESC) guidelines, baroreceptor 
stimulation may be considered in patients without effect 
after adequate drug treatment (Class IIb, Level C) [23]. 
But, baroreceptor stimulation was only recommended 
to experienced operators and selected hypertension cen-
tres until more evidence becomes available on long-term 
efficacy and safety (Class I, Level C).
Trial), which randomised 265 patients in the US and in 
Europe. It was the first large-scale randomised double-
blinded placebo-controlled trial to evaluate baroreflex 
activation therapy (BAT) in drug-resistant hypertension 
patients. One month after implantation of the Rheos 
system, the patients were randomised in a 2:1 fashion to 
either immediately turning on the device or to a 6-month 
deferral with device initiation thereafter. Both patient 
groups were followed for 12 months after randomisa-
tion. The trial demonstrated a mean reduction in SBP 
of 35  mmHg at 12 months. More than 50 % of patients 
attained a SBP ≤ 140  mmHg, which was very promising 
[15, 16]. Initially, a mild decrease of the glomerular fil-
tration rate was observed in these patients after initiat-
ing BAT, which was considered a normal haemodynamic 
response to the drop in blood pressure. However, in the 
long-term, there was no further decrease in renal func-
tion [17].
Moreover, a substudy of DEBuT-HT involved 21 
patients and analysed the correlation between blood 
pressure changes and changes in cardiac autonomic reg-
ulation after chronic baroreceptor stimulation [18]. In this 
study, chronic baroreceptor stimulation caused changes 
in heart rate variability, which was consistent with a 
sympathetic inhibition and a parasympathetic activation 
with correlating pressure reductions. The authors con-
cluded that further studies were needed to investigate 
whether this autonomic (sympathetic) modulation might 
have favourable cardiovascular effects in patients with 
drug-resistant systemic hypertension exceeding pure 
blood pressure control. In support hereof, another study 
demonstrated that chronic Rheos® Therapy reversed left 
ventricular and atrial remodelling and improved arte-
rial compliance in addition to sustained blood pressure 
reduction in patients with resistant hypertension [19]. 
These benefits were supplementary to those achieved by 
aggressive medical therapy and, potentially, indepen-
dent of isolated blood pressure reduction. Moreover, in 
Fig. 6 Feasibility long-term 
study. Decrease in systolic 
and diastolic blood pressure 
and heart rate after 1, 2, 3 and 
4 years of baroreflex activation 
therapy. Mean systolic blood 
pressure was reduced from 
193/111 mmHg (baseline) to 
140/81 (4-year results), N = 18 
[28]. bpm beats per minute
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Current status
At the end of August 2014, a total of 420 Rheos® devices 
and 380 Barostim neoTM systems have been implanted 
worldwide and 8 devices in our institution. Approxi-
mately 400 devices have been implanted in study set-
tings. All reports suggest so far that implantation can be 
performed with reasonable safety and that the associated 
risks are comparable with similar implantable devices 
such as pacemakers or ICDs.
In Europe, the Barostim neoTM device is already CE 
marked and commercially available in Italy, Germany, 
Switzerland and the Netherlands. Reimbursement is not 
yet regulated everywhere, but the therapy is currently 
in the process of being reimbursed in several European 
countries. An analysis has showed that the therapy is 
cost-effective in treating hypertension [24].
Conclusion
The BAT by the CVRx electrical carotid sinus wall stimu-
lation system leads to sustained arterial blood pressure 
decrease in selected patients with resistant hyperten-
sion. The haemodynamic response is larger than antici-
pated and sustained at 4-year follow-up complying with 
the treatment goal of sympathetic modulation leading to 
decreased sympathetic activity. Besides, lowered arterial 
blood pressure and heart rate led to favourable cardio-
vascular effects in patients with drug-resistant systemic 
hypertension like reversed left ventricular, atrial remod-
elling and improved arterial compliance. Studies on 
heart failure patients are ongoing and beneficial effects 
have been seen in selected patients. Thus, target popula-
tions include patients with refractory hypertension and 
eventually heart failure who do not respond sufficiently 
to best medical therapy. BAT has been incorporated in 
the 2013 ESH/ESC guidelines. The implantation of the 
second-generation device is less invasive and might be 
more likely to convince physicians and patients for the 
implantation. As in pacemakers, the development of 
rechargeable batteries is desirable for the future. More-
over, a feedback mechanism that activates the pulse gen-
erator only when increasing blood pressure is strongly 
awaited.
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